Citations

Citations to this article as recorded by  

• A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
  Ritesh R. Kotecha, Sahil D. Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J. Shah, Emily Feld, David H. Aggen, William Rafelson, Han Xiao, Maria I. Carlo, Darren R. Feldman, Chung-Han Lee,
  European Urology Oncology.2024; 7(4): 804.     CrossRef
• Hereditary Renal Cancer Syndromes
  Grigory A. Yanus, Ekaterina Sh. Kuligina, Evgeny N. Imyanitov
  Medical Sciences.2024; 12(1): 12.     CrossRef
• Fumarate Hydratase-Deficient Renal Cell Carcinoma—A Clinicopathological Study of a Series of 11 Cases
  Aswathy A. Menon, Swapnil Rane, Uma Sakhadeo, Gagan Prakash, Amit Joshi, Mahendra Pal, Amandeep Arora, Nilesh Sable, Aparna Katdare, Palak Popat, Priyamvada Maitre, Archi Agarwal, Vedang Murthy, Sangeetha B. Desai, Santosh Menon
  Indian Journal of Medical and Paediatric Oncology.2024;[Epub]     CrossRef
• Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
  Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Jingjing Guo, Jianhui Chen, Yongquan Wang, Xinan Sheng, Haiying Dong, Xiaodong Liu, Xingming Zhang, Jiayu Liang, Haolin Liu, Jin Yao, Jiyan Liu, Yali Shen, Zhibin Chen, Zhengyu He, Yaodong Wang, N
  Clinical Cancer Research.2024; 30(11): 2571.     CrossRef
• Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma
  Anna Caliò, Stefano Marletta, Lavinia Stefanizzi, Lisa Marcolini, Matteo Rotellini, Gabriella Serio, Elena Bariani, Caterina Vicentini, Serena Pedron, Filippo M. Martelli, Pietro Antonini, Matteo Brunelli, Guido Martignoni
  Modern Pathology.2024; 37(9): 100561.     CrossRef
• Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
  Elena Chitoran, Vlad Rotaru, Sinziana-Octavia Ionescu, Aisa Gelal, Cristina-Mirela Capsa, Roxana-Elena Bohiltea, Madalina-Nicoleta Mitroiu, Dragos Serban, Giuseppe Gullo, Daniela-Cristina Stefan, Laurentiu Simion
  Cancers.2024; 16(14): 2590.     CrossRef
• Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
  Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
  Cancer Research and Treatment.2024; 56(3): 721.     CrossRef
• Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
  Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
  Journal of Pathology and Translational Medicine.2024; 58(4): 147.     CrossRef
• Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma
  Isabella Portugal, Maria A. Clavijo-Salomon
  npj Precision Oncology.2024;[Epub]     CrossRef
• Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
  Yunze Xu, Wen Kong, Ming Cao, Jieying Wang, Zaoyu Wang, Liang Zheng, Xiaoyu Wu, Rongrong Cheng, Wei He, Bo Yang, Baijun Dong, Jiahua Pan, Yonghui Chen, Jiwei Huang, Chen Jiang, Wei Zhai, Fangzhou Li, Ruohua Chen, Xiang Zhou, Guangyu Wu, Xiaochuan Geng, Ji
  European Urology.2023; 83(2): 163.     CrossRef
• Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
  Alexius John, Lavinia Spain, Anis A. Hamid
  Current Oncology.2023; 30(1): 923.     CrossRef
• CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds
  Alexey A. Lagunin, Anastasia V. Rudik, Pavel V. Pogodin, Polina I. Savosina, Olga A. Tarasova, Alexander V. Dmitriev, Sergey M. Ivanov, Nadezhda Y. Biziukova, Dmitry S. Druzhilovskiy, Dmitry A. Filimonov, Vladimir V. Poroikov
  International Journal of Molecular Sciences.2023; 24(2): 1689.     CrossRef
• Fumarate Hydratase-deficient Renal Cell Carcinoma
  Yi-Hsuan Huang, Nan-Haw Chow, Yu-Ting Yu, Wen-Pin Su
  Journal of Cancer Research and Practice.2023; 10(1): 28.     CrossRef
• Diseases of Hereditary Renal Cell Cancers
  Othon Iliopoulos
  Urologic Clinics of North America.2023; 50(2): 205.     CrossRef
• Hereditary Leiomyomatosis and Renal Cell Cancer: A Case Report of Pilar Leiomyomatosis with History of Kidney Cancer and Review of the Literature
  Jee-Woo Kim, Jung-Won Shin, Anna Cho, Chang-Hun Huh
  Annals of Dermatology.2023;[Epub]     CrossRef
• Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
  Xinfeng Hu, Congzhu Tan, Guodong Zhu
  Current Issues in Molecular Biology.2023; 45(6): 4763.     CrossRef
• Hereditary predisposition to kidney cancer: cancer syndromes, multisystemic disorders, and nephropathies
  G. A. Yanus, A. G. Iyevleva, E. N. Suspitsin, A. V. Tumakova, E. V. Belogubova, S. N. Aleksakhina, A. V. Togo, E. N. Imyanitov
  Sechenov Medical Journal.2023; 14(2): 5.     CrossRef
• Hereditary leiomyomatosis and renal cell cancer associated with metastatic rectal cancer
  Parikshit Padhi, Naga Praneeth Raja
  Current Problems in Cancer: Case Reports.2023; 11: 100257.     CrossRef
• Unmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma
  Mirza Rameez Samar, Wajiha Khan, Yasmin Abdul Rashid, Azmina Tajuddin Vali Mohammad
  International Journal of Surgery Case Reports.2023; 113: 109054.     CrossRef
• Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities
  Alexander S. Taylor, Stephanie L. Skala
  Urologic Oncology: Seminars and Original Investigations.2022; 40(12): 499.     CrossRef
• Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female
  Nicolas Wyvekens, William J. Anderson, Young X. Kim, Mark Carter, Michelle S. Hirsch
  International Journal of Surgical Pathology.2022; 30(2): 184.     CrossRef
• Response to the Letter to the Editor Entitled “Do We Have Sufficient Evidence to Define Prognosis for ‘Low-grade’ Fumarate Hydratase-deficient Renal Cell Carcinoma?”
  Steven C. Smith, Ameer Hamza, Deepika Sirohi, Mahul B. Amin
  Advances in Anatomic Pathology.2022; 29(3): 181.     CrossRef
• Hereditary Renal Cell Carcinoma
  Scott J. Dawsey, Shilpa Gupta
  Kidney Cancer.2022; 6(2): 83.     CrossRef
• A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
  Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
  Clinical Genitourinary Cancer.2022; 20(5): 415.     CrossRef
• Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
  Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, Peter J. Siska, Martin Thurnher, Renate Pichler
  Frontiers in Oncology.2022;[Epub]     CrossRef
• MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome
  Guangyu Wu, Guiqin Liu, Jianfeng Wang, Shihang Pan, Yuansheng Luo, Yunze Xu, Wen Kong, Peng Sun, Jianrong Xu, Wei Xue, Jin Zhang
  Radiology.2022; 305(3): 631.     CrossRef
• Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report
  Yasuhiro Iribe, Mitsuko Furuya, Yousuke Shibata, Masato Yasui, Makoto Funahashi, Junichi Ota, Hiromichi Iwashita, Yoji Nagashima, Hisashi Hasumi, Narihiko Hayashi, Kazuhide Makiyama, Keiichi Kondo, Reiko Tanaka, Masahiro Yao, Noboru Nakaigawa
  Familial Cancer.2021; 20(1): 75.     CrossRef
• Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
  Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park
  Annals of Laboratory Medicine.2021; 41(2): 207.     CrossRef
• Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
  Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindon
  Clinical Cancer Research.2021; 27(6): 1734.     CrossRef
• Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
  Marianne Spengler, Megan Wheelden, Heath B. Mackley, Joseph J. Drabick
  JCO Precision Oncology.2021; (5): 664.     CrossRef
• Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
  Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
  Cancers.2021; 13(9): 2170.     CrossRef
• Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
  Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Pailleret
  European Journal of Cancer.2021; 151: 106.     CrossRef
• Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
  Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng
  Frontiers in Oncology.2021;[Epub]     CrossRef
• Hereditary leiomyomatosis and renal cell cancer presenting as urothelial carcinoma
  Samuel B Reynolds, Rishi Charate, Quang L Nguyen, Padmini Moffett
  Journal of Onco-Nephrology.2021; 5(3): 178.     CrossRef
• Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papillären Tumoren in der Niere
  N. Rupp, H. Moch
  Der Pathologe.2021; 42(6): 560.     CrossRef
• To treat or not to treat: a clinical series of retinal arterial macroaneurysms
  Wan-Hua Cho, Wei-Yu Chiang, Chih-Hsin Chen, Hsi-Kung Kuo
  Medicine.2020; 99(5): e19077.     CrossRef
• Bevacizumab/erlotinib
  
  Reactions Weekly.2020; 1798(1): 61.     CrossRef
• On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
  Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
  American Society of Clinical Oncology Educational Book.2020; (40): 418.     CrossRef
• Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
  Nicolas Wyvekens, Nadejda Valtcheva, Axel Mischo, Birgit Helmchen, Thomas Hermanns, Matthias Choschzick, Andreas M. Hötker, Anita Rauch, Beda Mühleisen, Dilara Akhoundova, Achim Weber, Holger Moch, Niels J. Rupp
  Genes, Chromosomes and Cancer.2020; 59(11): 611.     CrossRef
• Fumarate hydratase as a therapeutic target in renal cancer
  Priyanka Kancherla, Michael Daneshvar, Rebecca A. Sager, Mehdi Mollapour, Gennady Bratslavsky
  Expert Opinion on Therapeutic Targets.2020; 24(9): 923.     CrossRef
• Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma
  Shuheng Bai, YinYing Wu, Yanli Yan, Shuai Shao, Jiangzhou Zhang, Jiaxin Liu, Beina Hui, Rui Liu, Hailin Ma, Xiaozhi Zhang, Juan Ren
  Scientific Reports.2020;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
  Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
  Journal of Clinical Oncology.2024; 42(5): 507.     CrossRef
• A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
  Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
  Cancer Research and Treatment.2024; 56(1): 37.     CrossRef
• Extracellular vesicles as tools and targets in therapy for diseases
  Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
  Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
• Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
  Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
  Oral Oncology.2024; 151: 106739.     CrossRef
• Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
  Lei Liu, Qiang Liu
  Scientific Reports.2024;[Epub]     CrossRef
• The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
  Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
  Biomolecules.2024; 14(8): 925.     CrossRef
• Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
  Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
  Frontiers in Oncology.2024;[Epub]     CrossRef
• Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
  Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
  Virchows Archiv.2024;[Epub]     CrossRef
• FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
  Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
  Scientific Reports.2023;[Epub]     CrossRef
• Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
  Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
  OncoImmunology.2023;[Epub]     CrossRef
• Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
  Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
  Biomedicines.2023; 12(1): 24.     CrossRef
• New Treatment Development for Larynx Preservation
  Susumu Okano
  Koutou (THE LARYNX JAPAN).2023; 35(2): 98.     CrossRef
• Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
  Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
  Current Treatment Options in Oncology.2022; 23(2): 254.     CrossRef
• EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
  Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
  Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
  Diagnostics.2022; 12(5): 1071.     CrossRef
• Unraveling most abundant mutational signatures in head and neck cancer
  Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
  International Journal of Cancer.2021; 148(1): 115.     CrossRef
• Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
  Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
  Critical Reviews in Oncology/Hematology.2021; 160: 103284.     CrossRef
• Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
  Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
  Cancers.2021; 13(7): 1714.     CrossRef
• Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
  Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
  Processes.2021; 9(5): 792.     CrossRef
• Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
  Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
  International Journal of Molecular Sciences.2021; 22(9): 4981.     CrossRef
• A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
  Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
  Cancer Medicine.2021; 10(20): 7012.     CrossRef
• Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
  Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
  Journal of Clinical Investigation.2021;[Epub]     CrossRef
• Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
  Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
  Applied Sciences.2021; 11(24): 12079.     CrossRef
• Immunologic and immunogenomic aspects of tumor progression
  Andrea Ladányi, József Tímár
  Seminars in Cancer Biology.2020; 60: 249.     CrossRef
• Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
  Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
  Medical Oncology.2020;[Epub]     CrossRef
• Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
  Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
  Frontiers in Oncology.2020;[Epub]     CrossRef
• Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
  Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
  British Journal of Cancer.2020; 122(11): 1649.     CrossRef
• Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
  Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
  BMC Cancer.2020;[Epub]     CrossRef
• Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
  Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
  Scientific Reports.2020;[Epub]     CrossRef
• Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
  Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
  Cancers.2020; 12(7): 1777.     CrossRef
• Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
  Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
  British Journal of Cancer.2020; 123(12): 1720.     CrossRef
• Mutationssignaturen beim Kopf- und Hals-Tumor
  M. Plath, J. Hess, K. Zaoui
  HNO.2020; 68(12): 922.     CrossRef
• BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
  Hein Chun, Sangwoo Kim, Inanc Birol
  Bioinformatics.2019; 35(22): 4806.     CrossRef
• Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
  Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
  Frontiers in Oncology.2019;[Epub]     CrossRef
• A Review of HPV-Related Head and Neck Cancer
  Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
  Journal of Clinical Medicine.2018; 7(9): 241.     CrossRef

Citations

Citations to this article as recorded by  

• Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma
  Kimmen Quan, Philip Sutera, Karen Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert Zeh, Nathan Bahary, Ronald Stoller, Dwight E. Heron
  Practical Radiation Oncology.2018; 8(2): 95.     CrossRef
• A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
  Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim, Chang Duck Kim, Dong Ki Lee, Kwang Bum Cho, Chang Min Cho, Jong Ho Moon, Dong Uk Kim, Dae Hwan Kang, Youn
  Medicine.2017; 96(1): e5702.     CrossRef
• Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
  P. Jiménez-Fonseca, M. P. Solis, M. Garrido, L. Faez, D. Rodriguez, A. L. Ruiz, M. L. Sanchez Lorenzo, E. Uriol, M. D. Menendez, J. M. Viéitez
  Clinical and Translational Oncology.2015; 17(5): 384.     CrossRef
• Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
  Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, Marniza Saad, Adlinda Alip, Wan Zamaniah Wan Ishak
  Asian Pacific Journal of Cancer Prevention.2015; 16(4): 1449.     CrossRef
• An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
  Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li, Ke-Qing Qian
  Asian Pacific Journal of Cancer Prevention.2015; 16(14): 5681.     CrossRef
• Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
  Ibrahim Vedat Bayoglu, Umut Varol, Ibrahim Yildiz, Ugur Muslu, Ahmet Alacacioglu, Yuksel Kucukzeybek, Murat Akyol, Lutfiye Demir, Ahmet Dirican, Suna Cokmert, Yasar Yildiz, Bulent Karabulut, Ruchan Uslu, Mustafa Oktay Tarhan
  Asian Pacific Journal of Cancer Prevention.2014; 15(17): 7119.     CrossRef
• Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
  Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
  Cancer Research and Treatment.2014; 47(2): 266.     CrossRef
• Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
  Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
  PLoS ONE.2014; 9(8): e104346.     CrossRef
• Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance
  Chunfang Xu, Airong Wu, Hua Zhu, Huaying Fang, Lele Xu, Jianxin Ye, Jiaqing Shen
  Biomedicine & Pharmacotherapy.2013; 67(2): 133.     CrossRef

Citations

Citations to this article as recorded by  

• A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility
  Se-Lyun Yoon, Yun-Gil Roh, In-Sun Chu, Jeonghoon Heo, Seung Il Kim, Heekyung Chang, Tae-Hong Kang, Jin Woong Chung, Sang Seok Koh, Vladimir Larionov, Sun-Hee Leem
  Experimental & Molecular Medicine.2016; 48(7): e246.     CrossRef
• Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
  Ningning He, Nayoung Kim, Mee Song, Choa Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyunga Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills, Sukjoon Yoon
  Molecular Cancer Therapeutics.2014; 13(10): 2463.     CrossRef
• Hot embossed polyethylene through-hole chips for bead-based microfluidicdevices
  Jie Chou, Nan Du, Tina Ou, Pierre N. Floriano, Nicolaos Christodoulides, John T. McDevitt
  Biosensors and Bioelectronics.2013; 42: 653.     CrossRef
• Discovery and Evaluation of Polymorphisms in theAKT2andAKT3Promoter Regions for Risk of Korean Lung Cancer
  Jae Sook Sung, Kyong Hwa Park, Seung Tae Kim, Yeul Hong Kim
  Genomics & Informatics.2012; 10(3): 167.     CrossRef